Chest
Recent Advances in Chest MedicineClinical Approach to the Therapy of Asthma-COPD Overlap
Section snippets
Why Has ACO Become a Renewed Focus of Interest?
Asthma and COPD have been recognized now for centuries. The potential for overlap has been well described, and the concept that asthma and COPD share common origins was conceived more than half a century ago.15 Why then has there been an increased interest in this subgroup of patients in recent years? This may reflect an increased attention to disease phenotyping because precision medicine approaches require more refined understanding of disease heterogeneity. Along with this is the combination
Management Strategies for Asthma, COPD, and ACO
The Global Strategy for Asthma Management and Prevention and the Global Strategy for the Diagnosis, Management, and Prevention of COPD19 provided approaches for the diagnosis and management of ACO. However, these approaches were based mainly on expert opinion rather than patient outcomes data, reflecting an overall need for well-designed studies that address the management of this population. Nevertheless, these strategies provide a starting point for clinicians who encounter these patients in
Contrasting Therapies of Asthma and COPD in Mild/Moderate Disease
Inhaled medications are the foundation of therapy for both asthma and COPD. The treatment of these diseases uses a stepwise or escalation approach based on symptoms and exacerbations.22, 23 However, there is a key distinction between both treatment algorithms: specifically, the introduction of inhaled corticosteroids (ICSs) (Fig 1). In asthma, ICSs are introduced early in the treatment for patients who are symptomatic. ICSs decrease the risk of severe exacerbations, improve asthma control, and
Contrasting Therapies of Asthma and COPD in Severe Disease
Both severe asthma and COPD are characterized by worsening respiratory symptoms, frequent exacerbations and increased health-care utilization.47, 48 In these advanced stages, the treatment may require triple therapy with ICS, LABA, and LAMA (Fig 1). In COPD, triple therapy has been shown to improve lung function and exacerbation rates without increasing adverse events compared with dual therapy and placebo.49, 50, 51 For instance, a recent study by Vestbo et al52 showed that triple therapy
Role of Biomarkers in ACO
The use of biomarkers to identify patients who may benefit from therapy is well established in asthma.55, 56 In COPD, this method has accumulating evidence of benefits.60, 61 Although this approach might appear to be particularly useful to identify the ACO population, to date there is no biomarker that best encompasses the biologic mechanisms of this overlap. In fact, evidence suggests that ACO is a heterogeneous group encompassing several phenotypes of disease, including both eosinophilic and
Therapeutic Guidance
In patients with ACO who remain symptomatic despite inhaled therapies, an in-depth evaluation is required to determine the presence of treatable traits, which may aid in the diagnosis and provide therapeutic guidance.46 Further work is needed to help clinicians select the most appropriate therapy. Predictors of response in chronic airways disease is an area of intense research. Elevated serum levels of IgE, exhaled fraction of nitric oxide, and peripheral blood eosinophilia not only provide
Conclusions
There is still much to learn about the spectrum of ACO. Because asthma and COPD are inherently heterogeneous, future studies that include well-characterized and richly phenotyped cohorts of patients with features of both asthma and COPD, with varying degrees of severity and exacerbation history, are needed to better study disease interactions, risk factors, and prognostic makers.89 A gap clearly exists in the evidence for therapy in ACO, particularly in severe disease. Nevertheless, in clinical
Acknowledgments
Authors contributions: D. J. M. is the guarantor of this article. D. J. M. and F. J. M. contributed to conception, manuscript writing, and manuscript review. M. H. and S. A. C. contributed to manuscript writing and manuscript review. N. A. H., S. G. A, A. A., J. I. P., and M. K. H. contributed to interpretation of data and critical revisions. C. P. H. contributed to interpretation of data and critical revisions.
Financial/nonfinancial disclosures: The authors have reported to CHEST the
References (89)
- et al.
Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis
Lancet Respir Med
(2014) - et al.
Understanding asthma-chronic obstructive pulmonary disease overlap syndrome
Respir Med
(2016) - et al.
The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?
Lancet Respir Med
(2015) - et al.
Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma
Chest
(2014) - et al.
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Lancet
(2003) - et al.
Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma
Chest
(2006) - et al.
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
Chest
(2006) - et al.
Cardiovascular safety of tiotropium in patients with COPD
Chest
(2010) - et al.
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD
Respir Med
(2012) - et al.
Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study
Respir Med
(2012)
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
Lancet
What is the role of tiotropium in asthma?: a systematic review with meta-analysis
Chest
Improvements with tiotropium in COPD patients with concomitant asthma
Respir Med
Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review
Chest
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
J Allergy Clin Immunol
Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD
Chest
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2A study
Lancet Respir Med
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
Lancet
Roflumilast for asthma: efficacy findings in placebo-controlled studies
Pulm Pharmacol Ther
Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies
Pulm Pharmacol Ther
Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
Lancet
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes
J Allergy Clin Immunol
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
Lancet Respir Med
Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort
Lancet Respir Med
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
Lancet Respir Med
Mortality in the United States, 2014
NCHS Data Brief
The global economic burden of asthma and chronic obstructive pulmonary disease
Int J Tuberc Lung Dis
The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population
PLoS One
What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion
Eur Respir J
Analysis of asthma-chronic obstructive pulmonary disease overlap syndrome defined on the basis of bronchodilator response and degree of emphysema
Ann Am Thorac Soc
The clinical features of the overlap between COPD and asthma
Respir Res
The clinical and genetic features of COPD-asthma overlap syndrome
Eur Respir J
Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses
J Asthma
Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population
COPD
Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis
PLoS One
Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease
J Allergy Clin Immunol
Tiotropium in asthma poorly controlled with standard combination therapy
N Engl J Med
Clinical research: the influence of the pharmaceutical industry
Eur J Clin Pharmacol
Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study
BMJ
Symptom-based questionnaire for differentiating COPD and asthma
Respiration
Cited by (44)
Emerging applications and prospects of NFκB decoy oligodeoxynucleotides in managing respiratory diseases
2023, Chemico-Biological InteractionsGlucocorticoids and COVID-19
2022, Pharmacological ResearchCitation Excerpt :GCs are currently employed in treating several types of inflammatory lung disorders, although their efficacy is not always guaranteed. Among lung inflammatory diseases, asthma and COPD occupy a special place because of their high frequency (more than 500 million people worldwide affected) [85]. Asthma is a respiratory disease caused by hyperresponsiveness of the airways to environmental factors and commonly manifested by cough, dyspnea, and/or wheezing [86].
Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap
2022, Immunology and Allergy Clinics of North AmericaCitation Excerpt :As discussed elsewhere in this series, much controversy exists about the exact definition and prevalence of ACO between studies, but most studies suggest that the prevalence of ACO ranges between 1.1% and 4.5% in the general population but is considerably higher in asthma and COPD populations, with a reported prevalence of 27% and 33%, respectively.1–5 Because of heterogeneity of ACO and lack of consensus on its definition, therapeutic approach to this disease is based on treating both the underlying asthma and COPD and has been based only on consensus statements and expert opinions6–11; this is compounded by the fact that patients with ACO have been excluded from clinical trials evaluating asthma and COPD therapies. Furthermore, patients with ACO have several phenotypes and clinical presentations, and thus having one therapeutic approach may be problematic.
Epidemiology and outcome of pressure injuries in critically ill patients with chronic obstructive pulmonary disease: A propensity score adjusted analysis
2022, International Journal of Nursing StudiesCitation Excerpt :Well-described risk factors for pressure injury are poor mobility, impaired skin perfusion, malnutrition, and an overall higher burden of underlying conditions, all of which are well-recognized features of COPD (National Pressure Ulcer Advisory Panel, 2019). In the COPDGene project (Maselli et al., 2019) commonly occurring comorbidities included chronic heart failure, osteoporosis, stroke, peripheral vascular disease, gastroesophageal reflux disease, coronary heart disease, hypertension, and stomach ulcers. In our study, more COPD than non-COPD patients had chronic heart failure, impaired mobility, peripheral vascular disease, chronic renal failure, diabetes mellitus, and malnutrition.